Advertisement


Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Advertisement